<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1704">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138978</url>
  </required_header>
  <id_info>
    <org_study_id>ERO-2015-PLA-07-RPS</org_study_id>
    <nct_id>NCT05138978</nct_id>
  </id_info>
  <brief_title>Metagenomic and Metatranscriptomic Analysis of Clinical Plaque Samples</brief_title>
  <official_title>Metagenomic and Metatranscriptomic Analysis of Clinical Plaque Samples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colgate Palmolive</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Colgate Palmolive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the metagenomic and metatranscriptomic analysis&#xD;
      of clinical samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a blinded, non-randomized, crossover design. Subjects who meet the&#xD;
      inclusion/exclusion criteria will be enrolled in the study. Following enrollment, subjects&#xD;
      will be asked to use a washout dentifrice (#200000035883/001/000) for a minimum of 1 week.&#xD;
      Fasting plaque will be collected at Baseline and then again at a duplicate baseline&#xD;
      collection up to 1 week after the baseline collection. Subjects will be assigned a new&#xD;
      dentifrice (#200000035883/001/000) to use for 12 weeks. After 12 weeks' use, fasting plaque&#xD;
      will be collected. There will be a duplicate plaque collection up to 1 week after 12 week&#xD;
      collection. Subjects will be given a new dentifrice (#200000040228/001/000) to use for the&#xD;
      next 24 weeks. After 24 weeks' use, fasting plaque will be collected, and there will be a&#xD;
      duplicate plaque collection up to 1 week after this collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2017</start_date>
  <completion_date type="Actual">October 17, 2018</completion_date>
  <primary_completion_date type="Actual">October 17, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each subject will be randomized.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DNA (metagenomic) sequences</measure>
    <time_frame>38 weeks</time_frame>
    <description>The primary outcome is to collect plaque following each treatment and to assess DNA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RNA (metatranscriptomic) sequences</measure>
    <time_frame>38 weeks</time_frame>
    <description>The primary outcome is to collect plaque following each treatment and to assess RNA</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Plaque</condition>
  <arm_group>
    <arm_group_label>Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toothpaste</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colgate Cavity Protection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Toothpaste</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer</intervention_name>
    <description>Toothpaste</description>
    <arm_group_label>Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colgate Cavity Protection</intervention_name>
    <description>Toothpaste</description>
    <arm_group_label>Colgate Cavity Protection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male and/or female subjects 16 years and above&#xD;
&#xD;
          -  Minimum of 20 natural uncrowned teeth (excluding third molars) must be present&#xD;
&#xD;
          -  Caries active subjects will have at least 3 active caries lesions (ICDAS score 1 - 3).&#xD;
             Caries free control subjects will either have ICDAS score 0 or ICDAS score of 1 - 3&#xD;
             where the lesion is inactive.&#xD;
&#xD;
          -  Available throughout entire study&#xD;
&#xD;
          -  Willing to use only assigned products for oral hygiene throughout the duration of the&#xD;
             study&#xD;
&#xD;
          -  Must give written informed consent&#xD;
&#xD;
          -  Must be in good general health&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Unwilling or unable to sign an Informed Consent Form&#xD;
&#xD;
          -  Advanced periodontal disease&#xD;
&#xD;
          -  Medical condition which requires premedication prior to dental visits/procedures&#xD;
&#xD;
          -  Diseases of the soft or hard oral tissues&#xD;
&#xD;
          -  Orthodontic appliances that interfere with clinical assessments&#xD;
&#xD;
          -  Impaired salivary function&#xD;
&#xD;
          -  Current use of drugs that can affect salivary flow&#xD;
&#xD;
          -  Use antibiotics 3 months prior to or during this study&#xD;
&#xD;
          -  Use of any arginine containing oral care products such as Colgate Sensitive Pro-Relief&#xD;
             and Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer dentifrices 3 months&#xD;
             prior to or during this study&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Participate in another clinical study 1 week prior to the start of the washout period&#xD;
             or during the study period&#xD;
&#xD;
          -  Use of tobacco products&#xD;
&#xD;
          -  Allergic to common dentifrice ingredients&#xD;
&#xD;
          -  Allergic to amino acids&#xD;
&#xD;
          -  Immune compromised individuals (HIV, AIDS, immuno-suppressive drug therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciana Rinaudi-Marron, DR</last_name>
    <role>Study Director</role>
    <affiliation>Colgate Palmolive</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King's College London Dental Institute, UK</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Listerine</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

